MFN News Items | Nanologica

Nanologica to Attend Conferences in Preparative Chromatography

31 March, 2022

Nanologica will be attending several chromatography conferences during the spring in connection to the launch of the company’s silica for preparative chromatography, NLAB Saga®. The road show starts on April 7 at Purify’22 Chromatography Purification Conclave in Hyderabad, India, where Nanologica’s CEO Andreas Bhagwani will give the inaugural address on Pharmaceutical Megatrends and the Fundamental Impact of Chromatography, and where Nanologica’s SVP Chromatography Katarina Alenäs will give a talk on New Generation Silica for Peptide

Nanologica deltar i konferenser för preparativ kromatografi

31 March, 2022

Nanologica kommer att delta i flera kromatografikonferenser under våren i samband med lanseringen av bolagets silika för preparativ kromatografi, NLAB Saga[®]. Första konferensen är Purify'22 Chromatography Purification Conclave den 7 april i Hyderabad, Indien, där Nanologicas vd Andreas Bhagwani håller invigningstalet Pharmaceutical Megatrends and the Fundamental Impact of Chromatography och där Nanologicas SVP Chromatography Katarina Alenäs kommer att hålla ett föredrag om New Generation Silica for Peptide Purification. I maj deltar Nanologica på två konferenser

Trading in Nanologica’s shares on Nasdaq Stockholm commences today

29 March, 2022

Nanologica AB (publ) announces that the company’s shares are admitted for trading on Nasdaq Stockholm's main market today. “Nanologica is about to launch a world-class product within chromatography that can cut costs for insulin manufacturers, which may enable treatment for more diabetes patients. At the same time, we are progressing our unique platform for local delivery of drugs to the lung through internal development, with the goal of giving patients with severe lung diseases access

Handeln i Nanologicas aktier på Nasdaq Stockholm inleds idag

29 March, 2022

Nanologica AB (publ) meddelar att bolagets aktier idag upptas till handel på Nasdaq Stockholms huvudmarknad. “Nanologica står i begrepp att lansera en produkt i världsklass inom kromatografi som kan sänka kostnaderna för insulintillverkare, vilket kan möjliggöra behandling för fler diabetespatienter. Samtidigt utvecklar vi vår unika plattform för lokal leverans av läkemedel till lungan, med målet att ge patienter med svåra lungsjukdomar tillgång till nya eller förbättrade behandlingar. Med ett högkvalificerat team och storskalig produktion snart

Nanologica Publishes Prospectus in Connection with the Listing on Nasdaq Stockholm

21 March, 2022

On 11 March 2022, Nanologica AB (publ) announced that Nasdaq Stockholm’s Listing Committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market, conditioned upon customary conditions being fulfilled. The prospectus prepared in connection with the listing has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Nanologica’s website www.nanologica.com and will be made available on the Swedish Financial Supervisory Authority’s website www.fi.se.

Nanologica offentliggör prospekt i samband med notering på Nasdaq Stockholm

21 March, 2022

Nanologica AB (publ) meddelade den 11 mars 2022 att Nasdaq Stockholms bolagskommitté godkänt att bolagets aktier upptas till handel på Nasdaq Stockholms huvudmarknad, villkorat av att sedvanliga villkor uppfylls. Det prospekt som upprättats i samband med noteringen har idag godkänts och registrerats av Finansinspektionen och finns nu tillgängligt på Nanologicas webbplats, www.nanologica.com, samt kommer finnas tillgängligt på Finansinspektionens webbplats, www.fi.se. Länk till prospekt: https://nanologica.com/wp-content/uploads/2022/03/Prospekt-Nanologica-2022-03-21.pdf Första dag för handel på Nasdaq Stockholm är tisdagen den 29

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.